GIST pipeline
Studies
Trials grouped by drug. Open a study for its arms and the response, survival, and safety figures a source reports.
28 studies across 17 of 17 drugs. 28 studies are in the file.
Atezolizumab + Imatinib1 study
- ATEZOGISTNCT05152472Phase 2Active, not recruitingn 58
Avapritinib2 studies
Belzutifan1 study
- NCT04924075NCT04924075Phase 2Recruitingn 355
Bezuclastinib + Sunitinib1 study
- PeakNCT05208047Phase 3Recruitingn 482
DCC-30091 study
- NCT06630234NCT06630234Phase 1/2Recruitingn 120
Envafolimab + Regorafenib1 study
- NCT06772233NCT06772233Phase 2Not yet recruitingn 100
Imatinib5 studies
- Imatinib Phase 3 dose trials (combined analysis on label)Registry id n/rPhase 3Completedn 1640
- S0033 (one of the dose trials)NCT00009906Phase 3Terminatedn 748
- Imatinib Phase 2 (400 vs 600 mg)Registry id n/rPhase 2Completedn 147
- Adjuvant Study 1 (ACOSOG Z9001)NCT00041197Phase 3Completedn 732
- Adjuvant Study 2 (SSG XVIII)NCT00116935Phase 3Completedn 400
NB0032 studies
- NB003 Phase 1NCT04936178Phase 1Completedn 258
- GISTAR-1NCT07379047Phase 2/3Recruitingn 255
NN3201 (KIT Antibody-drug Conjugate, MMAE)1 study
- NCT06805825NCT06805825Phase 1Recruitingn 67
Olverembatinib (HQP1351)2 studies
- HQP1351SJ0003NCT03594422Phase 1Recruitingn 100
- POLARIS-3NCT06640361Phase 3Recruitingn 40
Pimitespib + Imatinib1 study
- NCT05245968NCT05245968Phase 1Active, not recruitingn 78
Regorafenib1 study
- GRIDNCT01271712Phase 3Completedn 199
Ripretinib3 studies
Rivoceranib + Paclitaxel1 study
- NCT05905887NCT05905887Phase 2Recruitingn 48
Sunitinib1 study
- Study 1NCT00075218Phase 3Completedn 361
Velzatinib (IDRX-42, GSK6042981)3 studies
- StrateGIST 1NCT05489237Phase 1Active, not recruitingn 276
- StrateGIST 3NCT07218926Phase 3Recruitingn 450
- StrateGIST FrontlineNCT07585266Phase 3Recruitingn 800
Ziftomenib + Imatinib1 study
- NCT06655246NCT06655246Phase 1Recruitingn 135